The mechanisms whereby the gut mucosa tolerates trillions of commensal bacteria without developing inflammation remain poorly understood. A recent Science article reveals that gut innate lymphoid cells constrain inflammatory T cell responses to commensal bacteria by adopting a strategy usually deployed by thymic epithelial cells to negatively select self-reactive T cells.
Innate lymphoid cells (ILCs) promote intestinal immunity by releasing distinct sets of cytokines that mirror those produced by CD4 + T effector (Teff) cells [1] . Unlike ILCs, Teff cells express somatically recombined receptors that recognize antigen in the context of major histocompatibility class-II (MHC-II) molecules expressed on dendritic cells (DCs) [1] . The immunostimulating properties of Teff cells are constrained by CD4 + T regulatory (Treg) cells expressing the transcription factor Foxp3 [2] . These Treg cells maintain gut homeostasis in cooperation with various cell types, including ILCs expressing the transcription factor RORγt and known as ILC3.
ILC3 maintain epithelial integrity and stimulate mucus secretion by releasing interleukin-22 (IL-22) and lymphotoxin [1, 3, 4] , whereas Treg cells mitigate the pro-inflammatory activity of Teff cells by releasing transforming growth factor-β (TGF-β) and IL-10 [2] . Of note, these cytokines also stimulate B cell production of immunoglobulin A (IgA), a mucosal antibody class that controls commensal bacteria inhabiting the lumen of the gut [5] .
Unlike ILC3, Treg cells require instructive signals from DCs to exert their homeostatic function. After capturing intraluminal antigen through transepithelial dendrites, CX3CR1
+ macrophages transfer antigen to CD103 + DCs, which migrate to mesenteric lymph nodes (MLNs) to serve as antigenpresenting cells (APCs) for the generation of Foxp3 + Treg cells [6, 7] . Besides MHC-II-restricted cognate T-DC interactions, this process involves release of TGF-β by DCs and conversion of dietary vitamin A into a tolerogenic metabolite known as retinoic acid (RA) in DCs [7] .
Recent studies show that gut ILC3 induce Treg cells by releasing granulocyte monocyte-colony stimulating factor (GM-CSF) [8] . This cytokine elicits expression of RA in CD103 + DCs in response to IL-1β from macrophages [8] . Besides inducing Treg cell expansion, ILC3 constrain Teff cell expansion by establishing MHC-II-dependent cognate interactions [9] . However, how do MHC-II + ILC3 exert this suppressive activity? An elegant study by Hepworth et al. [10] + DCs from the gut lamina propria [6] . Accordingly, ILC3 can home to mucosal draining lymph nodes by following chemotactive gradients established by CCR7 ligands [11] .
Hepworth et al. [10] further found that MHC-II expression by ILC3 is uncoupled from expression of costimulatory molecules (Figure 1 ), even following activation by microbial or inflammatory stimuli. Studies from another group show that splenic ILC3 initiate productive CD4 + T cell responses after upregulating both MHC-II and co-stimulatory molecules upon exposure to inflammatory stimuli [12] . One possibility that may reconcile these discrepant findings is that ILC3 inhibit co-stimulatory molecule expression in response to tissue-specific condition-npg Nur77-controlled pathway that upregulates the pro-apoptotic protein Bim. A similar mechanism is also adopted by MHC-II + ILC3 to remove commensalreactive Teff cells (Figure 1) . However, this is not all. Indeed, Hepworth et al. [10] found that MHC-II + ILC3 express elevated levels of CD25, a high-affinity receptor for the T cell growth factor IL-2. By extracting IL-2 from the extracellular environment via CD25, MHC-II + ILC3 starve CD4 + Teff cells, thereby further restraining their expansion [10] . This finding may explain why MHC-II + ILC3 spare Treg cells (Figure 1) , which express elevated levels of CD25.
Finally, Hepworth et al. [10] found that the gut ILC3 expressed less MHC-II in patients with inflammatory bowel disease (IBD). Concomitantly, these patients also showed more pro-inflammatory gut Teff cells, including T helper 17 (Th17) cells [10] . Thus, perturbations of MHC-II expression by ILC3 may cause gut inflammation by impairing the negative selection of CD4 + Teff cells reactive to commensals (Figure 1) . This raises the possibility that IBD may benefit from drugs capable to restore MHC-II expression by ILC3. Further transcriptional studies revealed that gut ILC3 express MHC-II through a mechanism involving the pIV promoter of class II transactivator (CIITA), a co-activator of MHC-II genes also used by TECs [10] . By setting up elegant in vitro ILC3-CD4 + T cell co-cultures, Hepworth et al. [10] demonstrated that ILC3 activate a CD4 + T cell death program similar to that activated by TECs for the negative selection of developing CD4 + T cells. In the thymus, TECs eliminate autoreactive CD4 + T cells by presenting self-antigen in the context of MHC-II. The resulting TCR signals activate a + Teff cells due to defects of the molecular machinery supporting MHC-II expression. These defects induce expansion of Th17 cells.
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